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doi:10.1016/j.ejvs.2009.12.007Abstract Objective: We evaluated the incidence of aorto-oesophageal (AEF) and aortobron-
chial (ABF) fistulae after thoracic endovascular aortic repair (TEVAR), and investigated their
clinical features, determinants, therapeutic options and results.
Methods: We conducted a voluntary national survey among Italian universities and hospital
centres with a thoracic endovascular programme.
Results: Thirty-nine centres were contacted, and 17 participated. Of the patients who under-
went TEVAR between 1998 and 2008, 19/1113 (1.7%) developed AEF/ABF. Among indications to
TEVAR, aortic pseudo-aneurysm was associated with the development of late AEF/ABF
(P Z 0.009). Further, emergent and complicated procedures resulted in increased risk of
AEF/ABF (PZ 0.008 and P < 0.001, respectively). Eight patients were treated conservatively,
all of whom died within 30 days. Eleven patients underwent AEF/ABF surgical treatment, with
a perioperative mortality of 64% (7/11). At a mean follow-up of 17.7  12.5 months, overall
survival was 16% (3/19).
Conclusions: The incidence of AEF and ABF following TEVAR is not negligible, and is compa-
rable to that following open repair. This finding warrants an ad hoc long-term follow-up after
TEVAR, particularly in patients submitted to emergent and complicated procedures. Both
surgical and endovascular treatment of AEF/ABF are associated with high mortality. However,
conservative treatment does not appear to be a viable option.
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Table 1 Centres participating to the survey.
Institute Director
A.O. Molinette, Torino M. Rinaldi
A.O. Policlinico ‘‘G. Martino’’, Messina F. Spinelli
A.O. Policlinico ‘‘Le Scotte’’, Siena C. Setacci
A.O. S. Croce e Carle, Cuneo C. Novali
A.O. San Gerardo, Monza G. Biasi
A.O. San Martino, Genova D. Palombo
A.O. Spedali Civili di Brescia S. Bonardelli
Arcispedale S. Anna, Ferrara F. Mascoli
IRCCS Policlinico San Donato, Milano V. Rampoldi
IRCCS Policlinico San Donato, Milano D. Tealdi
IRCCS Policlinico San Matteo, Pavia A. Odero
IRCCS San Raffaele, Milano R. Chiesa
Ospedale di Imperia C. Bertoglio
Ospedale S.M. della Misericordia, Perugia P. Cao
Policlinico di Modena G. Coppi
Policlinico Umberto I, Roma F. Speziale
Presidio Ospedaliero di Lodi A. Argenteri
274 R. Chiesa et al.Aorto-oesophageal (AEF) and aortobronchial (ABF) fistulae
are uncommon and highly fatal conditions that occur most
frequently secondary to thoracic trauma, aortic aneurysms,
ruptured penetrating aortic ulcers, oesophageal or bron-
chogenic malignancies and thoracic surgery.1 In particular,
the incidence of AEF/ABF as a complication of open repair
of the thoracic and thoraco-abdominal aorta ranges from
0.5%e1.7%.2,3
Since its introduction in the early 1990s,4 thoracic
endovascular aortic repair (TEVAR) has become the most
important therapeutic alternative for high-risk patients
with thoracic aortic disease. With growing numbers of
interventional thoracic aortic procedures and increasing
follow-up periods, late complications of TEVAR have
become increasingly evident over time, including post-
procedural AEF and ABF.5e8 However, relatively little is
known about these sequelae because of their rarity, the
fairly recent clinical introduction of endovascular tech-
niques and the lack of multicentre reports.
The objective of this study was to evaluate the inci-
dence of post-TEVAR AEF/ABF, investigate clinical features
and determinants and assess the efficacy of therapeutic
measures by means of a national survey conducted in Italy.Methods
We conducted a cross-sectional survey on a voluntary basis
among Italian universities and hospital centres with
a thoracic endovascular programme. A text document-
based survey developed by us was distributed in November
2007 by e-mail to the medical directors of Italian depart-
ments of vascular surgery or cardiothoracic surgery known
to have experience with thoracic aorta stent grafting.
Centres that performed TEVAR on a regular basis, even if
they lacked direct experience with AEF/ABF treatment,
were invited to participate. Accompanying the question-
naire was a letter explaining the aims of the study and the
compiling modalities. Each centre that failed to respond
was contacted by telephone or solicited by e-mail. The
survey ended in December 2008. Participating centres
(listed in Table 1) were requested to provide data from
patients that underwent TEVAR for noninfectious aortic
disease between 1998 and 2008, and data from patients
presenting a post-TEVAR AEF and/or ABF in the same
period. In addition, data regarding results of endovascular
repair of an established AEF or ABF were collected within
the same survey. These data, however, pertain to different
patients with different pathologies, and were reported in
a separate publication.39 Patient names or identifiers were
not requested or provided.
Demographics and preoperative risk factors, including
coronary artery disease, pulmonary disease and renal
failure were defined as previously reported.9 The anatomic
location of the proximal landing zone was defined according
to the ‘aortic arch map’proposed by Ishimaru (0e4).10 The
results of TEVAR were described according to the reporting
standards for endovascular aortic aneurysm repair.11 Renal
dysfunction was defined as a rise in serum creatinine
exceeding the baseline value by 30% and surpassing an
absolute level of 2.0 mg dl1.12 Myocardial infarction was
suggested by electrocardiographic changes and confirmedby elevation of cardiac enzymes, regardless of symptoms.
Respiratory failure was defined as ventilator dependence
lasting >72 h, the need for postoperative reintubation,
clinical data or culture confirmation of pneumonia or the
need for tracheostomy.12
Patients were followed-up according to the protocol of
each institution; in all cases, this included thoracic
contrast-enhanced computed tomography (CT) or magnetic
resonance (MR) imaging and an outpatient clinical
evaluation.
Patients who developed AEF/ABF following TEVAR were
compared with the global cohort of patients who under-
went TEVAR in terms of preoperative and intra-operative
variables of interest, using the Fisher exact test or c2 test
for categorical data, and the unpaired t-test or Manne
Whitney test for continuous data, as appropriate. All
analyses were run using SAS 8.02 software (SAS Institute
Inc., Cary, NC, USA).
Results
In general, 17 out of the 39 contacted centres, including
that of the authors, provided patient data (Table 1).
Between 1998, 2008, 1113 patients underwent TEVAR. Of
these patients, 19 patients developed an AEF or ABF during
follow-up (1.7%). Demographics and preoperative risk
factors of patient presenting postoperative AEF/ABF are
summarised in Table 2. Three cases included in this survey
were reported in a previous series.13e15
Indications for TEVAR (Table 3) included atherosclerotic
aortic aneurysm, penetrating ulcer, intramural haema-
toma, acute and chronic dissection, traumatic injury,
coarctation and anastomotic pseudo-aneurysm following
previous aortic open repair. Only anastomotic pseudo-
aneurysm was significantly associated with AEF/ABF
development (16% vs. 2%; P Z 0.009). In addition,
emergently performed procedures were associated with
an increased risk of AEF/ABF (37% vs. 13%; P Z 0.008;
Table 3).
Table 2 Demographics, risk factors and procedural details
of patients presenting a postoperative AEF/ABF.
Characteristics No. Patients (%)
Overall 19
Age (years, mean  SD) 73.8  7.1
Gender (male) 16 (84)
Coronary artery disease 7 (37)
Diabetes mellitus 2 (10)
Hypertension 15 (79)
Cerebrovascular disease 3 (16)
Pulmonary disease 11 (58)
Renal failure 5 (26)
Smoking 7 (37)
American Society of Anaesthesiologists class
1 0 (0)
2 0 (0)
3 11 (58)
4 8 (42)
5 0 (0)
Proximal landing zone
Zone 0 0 (0)
Zone 1 1 (5)
Zone 2 2 (10)
Zone 3 8 (42)
Zone 4 8 (42)
Table 4 Stent grafts implanted in patients who developed
an AEF/ABF.
Stent-graft (Manufacturer) No. of
patients (%)
Endofit (Endomed Inc, Phoenix, Ariz) 3 (16)
Relay (Bolton Medical Inc, Sunrise, FL) 1 (5)
TAG (WL Gore and Assoc,Flagstaff, Ariz) 2 (10)
Talent (AVE/Medtronic Inc,
Santa Rosa, Calif)
8 (42)
Zenith TX1 (WilliamCook Europe
Aps, Bjaeverskov, Denmark)
2 (10)
Zenith TX2 (WilliamCook Europe
Aps, Bjaeverskov, Denmark)
3 (16)
Aorto-oesophageal and Aortobronchial Fistulae After TEVAR 275Six types of commercially available stent grafts from five
different manufacturers were employed (Table 4). The
mean stent graft proximal diameter was 37.9  5.3 mm.
A mean number of 1.4  0.5 devices per patient were
implanted. The mean aortic length to be covered was
171.8  61.1 mm. An intended stent graft oversizing at the
proximal landing zone of 10e19% was used in 11 cases
(58%), 20% in six cases (32%) and 21e30% in two cases (10%).Table 3 Comparison of indications and modality of
TEVAR, in the global cohort and in patients who developed
AEF/ABF.
Characteristics All TEVAR
patients
(%)
AEF/ABF
patients
(%)
P*
Overall 1113 19
Indication to TEVAR
Atherosclerotic
aneurysm
782 (70.3) 13 (68.4) .806
Penetrating ulcer/
Intramural haematoma
48 (4.3) 2 (10.5) .203
Acute dissection 74 (6.6) 0 (0.0) .630
Chronic dissection 98 (8.8) 0 (0.0) .399
Traumatic injury 83 (7.5) 1 (5.3) 1.0
Aortic coarctation 4 (0.4) 0 (0.0) 1.0
Anastomotic
pseudoaneurysm
24 (2.1) 3 (15.8) .009
TEVAR performed in
emergency
143 (12.8) 7 (36.8) .008
* Fisher exact test.Cerebrospinal fluid drainage was instituted in three
patients (16%). The mean duration of the procedure was
160  139 min, and the mean estimated blood loss
534  516 ml. Ballooning was performed in 12 cases (63%).
Concomitant supra-aortic vessel debranching was per-
formed in three cases (16%).
Primary technical success was obtained in 17/19 cases
(Table 5). One patient underwent implantation of a prox-
imal additional cuff to treat a type I endoleak. Perioper-
ative complications occurred in eight patients (42%),
including renal dysfunction in five cases, respiratory failure
in five cases and stroke in one case. Compared to the global
cohort of patients who underwent TEVAR, the occurrence
of perioperative complications was significantly associated
with late AEF/ABF development (42% vs. 12%; P < 0.001),
particularly in cases with postoperative renal dysfunction
(P < 0.001) and respiratory failure (P Z 0.001).
The mean interval between TEVAR and fistula detection
was 10.9  15.4 months. The fistula involved the oesoph-
agus in 13 cases (68%) and the left bronchial tree in one
case (5%); there was concomitant broncho-oesophageal
involvement in five cases (26%). The symptoms at presen-
tation and the diagnostic modalities that disclosed AEF/ABF
are reported in Table 6. In one patient who died of suddenTable 5 Comparison of TEVAR results, in the global cohort
and in patients who developed AEF/ABF.
Characteristics All TEVAR
patients
(%)
AEF/ABF
patients
(%)
P*
Overall 1113 19
Primary technical success 998 (89.7) 17 (89.5) 1.0
30-day morbidity: overall 129 (11.6) 8 (42.1) <.001
Paraplegia/paraparesis 47 (4.2) 0 (0.0) 1.0
Renal dysfunction 38 (3.4) 5 (26.3) <.001
Respiratory failure 48 (4.3) 5 (26.3) .001
Stroke 16 (1.4) 1 (5.3) .252
Myocardial infarction 18 (1.6) 0 (0.0) 1.0
Residual type I endoleak 48 (4.3) 1 (5.6)a .572
* Fisher exact test.
a Number of endoleaks detected among the 18 patients
submitted to preoperative CT scan.
276 R. Chiesa et al.haemorrhagic shock, an AEF was diagnosed only at autopsy.
CT scans performed upon admission revealed only one
associated endoleak in a patient who was previously
treated for a thoracic descending aortic aneurysm (1/18;
6%). No stent-graft fractures were observed. Blood cultures
were positive in three cases (16%). Isolated microorganisms
included Enterococcus sp. and Mycobacterium
tuberculosis.14
All of the patients who did not undergo any intervention
died within 30 days (8/8). Eleven patients (58%) underwent
AEF/ABF emergent repair (Table 7). Treatment included
aortic surgical repair in two patients, with associated
oesophageal reconstruction in one of them. Aortic re-
endografting was performed in three patients, with asso-
ciated oesophageal reconstruction in one of them. Six
patients underwent oesophageal and/or bronchial repair
alone (Fig. 1). Perioperative mortality was 64% (7/11). Of
the survivors, one patient died 6 months after the operation
due to unrelated causes. Another patient underwent
successful multiple re-interventions, including total oeso-
phagectomy and thoracic aortic reconstruction under deep
hypothermic circulatory arrest. At a mean follow-up of
17.7  12.5 months, the overall survival was 16% (3/19).
Discussion
First described by Dubrueil in 1818 and by Girardet in
1914,16,17 AEF and ABF are well-known rare causes of
massive gastrointestinal and respiratory bleeding that are
associated with high morbidity and mortality. Although the
most common cause of fistulisation is the erosion of
a thoracic aortic aneurysm,18 secondary AEF and ABF are also
known to develop late after thoracic aortic surgery in up to
1.7% of patients.2,3 Our survey revealed that the incidence of
post-TEVARAEF andABF is comparable to the incidence after
open repair surgery; therefore, in this respect, endovascular
treatment of the thoracic aorta does not appear to provide
any advantage over conventional repair.
We found that pseudo-aneurysm as an indication
for TEVAR represents a significant risk factor for lateTable 6 Clinical features at presentation and preopera-
tive diagnostic studies.
Variable No. Patients (%)
Total patients 19
Symptoms at presentation
Haematemesis/haemoptysis 13 (68)
Fever 11 (58)
Shock 5 (26)
Thoracic pain 1 (5)
Dyspnea 2 (10)
Dysphagia 1 (5)
Melena 4 (21)
Diagnostic studies showing AEF/ABF
Computed tomography 18 (95)
Gastrointestinal/bronchial endoscopy 6 (32)
Oesophagogram 1 (5)
Labeled leukocyte scintigraphy 1 (5)fistulisation. Compression of the oesophagus or the airways
by the pseudo-aneurysm may result in a local inflammatory
response, formation of stable adhesions and tissue necrosis,
leading to erosion and final fistulisation. Although endo-
vascular treatment has been proposed as a less-invasive
and safe alternative to open surgery for repair of thoracic
pseudo-aneurysms,19,20 our data show that TEVAR may lead
to long-term serious complications in this setting.
Endoluminal repair of thoracic aortic disease requiring
emergent or urgent treatment has yielded encouraging
early results with low morbidity and mortality rates
compared with open surgery.21 However, our survey
revealed that emergent TEVAR is associated with an
increased risk of late AEF/ABF development, indicating
a need for caution after these procedures. The mechanisms
underlying this finding are unclear, but we speculate that
aortic lesions that require emergent repair often entail
extravasation of blood and periaortic haematoma, with
increased local inflammatory response and compression of
surrounding organs. These factors, which are not amelio-
rated by aortic stent grafting, may play a role in late
fistulisation.22
We also found that the occurrence of perioperative
complications after TEVAR, particularly renal dysfunction
and respiratory failure, were significant predictors of AEF/
ABF development. A closer follow-up of these patients may
help to recognise AEF/ABF early, although there is no
evidence that early detection should improve the
prognosis.
Post-TEVAR fistulae have been reported to occur as
a result of endoleak into the residual aneurysm sac, erosion
of the stent graft through the aorta and ischaemic necrosis
of the oesophageal/bronchial wall resulting from stent
coverage of their feeding arteries.7,8,23 However, our
survey found that the rate of residual type I endoleak in
patients presenting an AEF/ABF was comparable to that of
the global cohort; only one patient had an endoleak at the
time of AEF detection. This result could be due to the low
incidence rate of endoleaks (type II error); therefore, we
believe that patients presenting endoleak should be always
closely followed up.
Different thoracic stent grafts were used in the patients
who developed AEF/ABF. Specific device characteristics, the
number of stent grafts used and the length of the covered
aorta were not significantly associated with AEF/ABF
development. We found that 42% of patients presenting late
AEF/ABF had a proximal oversizing of 20% or more, regard-
less of the manufacturer’s recommendations. Although this
cannot be appointed as a risk factor because the proportion
of oversized grafts in the global cohort of TEVAR patients is
unknown, excessive stent graft oversizing has been previ-
ously shown to result in long-term deterioration of the
arterial wall, stent-graft migration and aortic aneurysm
enlargement,24,25 and should be taken into account as
a possible additional mechanism of fistulisation.26,27
AEF/ABF were observed at different time intervals
during the follow-up, and therefore their occurrence
appears to be unpredictable. The most common present-
ing symptom was upper gastrointestinal or respiratory
bleeding, followed by chronic fever. CT scan was the first
imaging study performed in most of the cases, because it
is easy to carry out in emergency conditions. Although CT
Table 7 Clinical outcome in patients presenting a post-TEVAR AEF/ABF.
Pt. Gender,
age
AEF/ABF Treatment Outcome
#1 f, 76 AEF Thoracic aorta ligation þ extranatomic bypass
(‘‘Ventral aorta’’)
Death (perioperative)
#2 m, 69 AEF In situ aortic reconstruction þ bipolar oesophageal
exclusion
Death (perioperative)
#3 f, 58 AEF þ ABF Re-TEVAR (immediate) þ oesophagectomy and
gastric ‘‘pull-up’’ (2 months) þ in-situ aortic
reconstruction (14 months)
Alive at 30 months
#4 m, 75 AEF Re-TEVAR Death (perioperative)
#5 f, 82 AEF Re-TEVAR þ mediastinal drainage Death (perioperative)
#6 m, 70 AEF Bipolar oesophageal exclusion Death (perioperative)
#7 m, 84 AEF þ ABF Bipolar oesophageal exclusion þ bronchial repair Death (at 6 months)
#8 m, 69 AEF þ ABF Cervical oesophagostomy Death (perioperative)
#9 m, 61 AEF Oesophagectomy þ gastric ‘‘pull-up’’ Alive at 18 months
#10 m, 73 AEF þ ABF Oesophageal stent-grafting Death (perioperative)
#11 m, 70 AEF Oesophageal stent-grafting Alive at 5 months
#12 m, 78 ABF No treatment Death
#13 m, 78 AEF No treatment Death
#14 m, 83 AEF No treatment Death
#15 m, 80 AEF No treatment Death
#16 m, 73 AEF No treatment Death
#17 m, 75 AEF þ ABF No treatment Death
#18 m, 80 AEF No treatment Death
#19 m, 68 AEF No treatment Death
Aorto-oesophageal and Aortobronchial Fistulae After TEVAR 277scans rarely detect fistulous tracts, suggestive signs of
AEF/ABF are present in most patients, including air
bubbles into the thrombus, periaortic fluid collection,
oesophageal or bronchial wall thickening and lung
consolidation.19,28,29 Endoscopy is the most sensitive and
specific method for the diagnosis of AEF/ABF,30 but often
requires sedation and entails the risk of dislodging clots
during the progress of the endoscope, which can cause
fatal bleeding.31Figure 1 Aortoesophageal fistula following TEVAR. A) Preoperativ
B) Intra-operative photograph during surgical conversion shows thor
a silver-coated prosthetic graft.Mortality after surgery for thoracic aortic fistulae has
been shown to reach 61% in cases of primary etiology32 and
78% in cases of secondary fistulae.33 Conventional treat-
ment includes surgical aortic repair, which is most
commonly performed via a left posterolateral thoracotomy.
Recently, TEVAR was proposed as an alternative strategy
for the surgical management of AEF and ABF.34,35 Although
less-invasive, this technique presents important limita-
tions, mainly the high risk of graft contamination. Severale CT scan demonstrating air bubbles in the thrombus (arrows).
acic stent-graft removal, and aortic in situ reconstruction with
278 R. Chiesa et al.authors have proposed a variety of combinations of TEVAR
with surgical aortic repair, oesophageal stent grafting,
tracheobronchial or oesophageal reconstruction, medias-
tinal drainage or even endoscopic use of fibrin glue at the
level of the fistula.36e38 The long-term efficacy and safety
of these techniques, however, has yet to be determined.
The operative mortality of post-TEVAR AEF/ABF repair
was 63.6% in our series. No significant differences in terms
of either early or late mortality were observed between
AEF and ABF. Although, in our study, mortality appeared to
be independent of the surgical technique used, we cannot
make general recommendations for the surgical treatment
of AEF and ABF due to the small number of cases. Consis-
tent with previous findings, according to our survey, both
AEF and ABF were invariably fatal if left untreated.
In conclusion, although rare, AEF and ABF are consid-
erable late sequelae of TEVAR, particularly in patients who
underwent emergent procedures or who experienced peri-
operative complications. Both surgical and endovascular
treatment are associated with high mortality, but conser-
vative treatment is not a viable option. Further studies are
needed to assess the optimal management of these
complications.
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